AIRS

Image source: The Motley Fool. Monday, Aug. 10, 2026 at 8:30 a.m. ET Chief Executive Officer - Yogesh Jashnani Chief Financial Officer - Michael Arthur Operator: Greetings, and welcome to the AirSculpt Technologies, Inc. Second Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Allison Malkin with ICR. Please begin. Allison Malkin: Good morning, everyone. Thank you for joining us to discuss AirSculpt Technologies' results for the second quarter of fiscal 2026. Joining me on the call today are Yogesh Jashnani, Chief Executive Officer, and Michael Arthur, Chief Financial Officer. For this morning's call, Yogi will begin with a review of our second quarter results and the progress made on our strategic priorities, and Michael will share a detailed review of our second quarter and first six-month performance and guidance. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities, and our growth. Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release and the reports we will file with the SEC, all of which can be found on our website at investors.airsculpt.com. We undertake no obligation to revise or update any forward-looking statements or information except as required by law. During our call today, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions, as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-K, which will also be available on our website. With that, I'll turn the call over to Yogi. Yogesh Jashnani: Thank you, Allison, and good morning, everyone. Welcome to AirSculpt's second quarter earnings call. I am pleased to share that our second quarter and first half results marked meaningful progress on our transformation. For the quarter, on a comparable basis, we delivered stable revenue and positive same-center case growth. Center sales began the quarter positively and saw moderating sales trends in June, which we attribute to a dynamic consumer environment. Overall, we generated a 21-percentage-point improvement in same-center sales versus Q2 last year and a 23-percentage-point improvement year-to-date. Over the past 18 months, we have broadened our consumer reach to capture the growing opportunity presented by GLP-1 patients, bolstered our talent, invested in new marketing strategies, and strengthened our balance sheet to provide the financial flexibility to support future growth. Those actions are showing in the continued stabilization of the business with roughly flat same-center sales growth in the first half. Our near-term focus remains squarely on increasing same-center sales. Longer term, we believe there is meaningful growth in new procedures and de novo expansion. As our balance sheet and cash flow generation strengthen, we intend to expand our geographic footprint and center base over time. Let me now turn to our progress on the three strategic priorities. As a reminder, these are, first, introducing new services to capture our GLP-1 market opportunity; second, enhancing our sales and marketing strategy; and third, maintaining strong financial discipline. First, introducing new services to capture our GLP-1 market opportunity. GLP-1 continues to represent a significant long-term growth driver for AirSculpt, with nearly 19 million potential patients interested in body contouring or related aesthetic procedures over time. Our core body contouring procedures continue to resonate with GLP-1 patients, and we are expediting the expansion of our portfolio of procedures to serve their evolving aesthetic needs. During the quarter, we completed over 200 skin excision procedures and expanded the offering to additional centers. We also broadened our services to include upper blepharoplasty and mastopexy. These procedures further expand our addressable market and increase our center productivity, while allowing us to better serve the needs of our patients. We continue to expect this to represent a $100 million-plus long-term revenue opportunity across our existing base of centers with an increasing long-term potential as we resume de novos. As part of our strategy to expand our body contouring platform, today we are announcing a partnership with Tiger Aesthetics to offer AlloClae for patients. AlloClae is a structural adipose tissue allograft used for non-surgical body contouring designed to add subtle, natural-looking targeted volume. We are excited about this partnership for several reasons. First, it allows us to reach patients we previously could not serve, including those without enough fat for a traditional fat transfer. Second, we expect a quicker ramp as many of our surgeons are trained in this procedure already. And finally, consumer interest in this category continues to grow as the use of GLP-1 creates the need for targeted restoration of volume. We believe this further strengthens our ability to serve consumers across their entire aesthetics journey. AlloClae will start rolling into our centers later this quarter. Looking forward, we have additional procedures in the pipeline that are core to body contouring and are a strong fit for our brand. We remain focused on thoughtfully expanding our capabilities to enhance the patient experience and increase center productivity. Our second focus is enhancing our sales and marketing strategy. As we expand our portfolio of procedures, we're also evolving how we market and sell them. During the quarter, we refined our marketing through a test and learn approach, optimizing how we reach GLP-1 patients and educate prospective patients on our new procedures. As we fine-tune our marketing investments in these procedures, we expect to achieve a higher return on that spend, driving revenue growth and greater marketing efficiency. At the same time, we trained our sales team and implemented additional sales optimization tools to make them more efficient and effective, recognizing that selling these procedures requires a different approach than a traditional body contouring business. We believe these investments will enable us to better reach patients and improve commercial execution as our portfolio continues to grow. Third area of focus is maintaining strong financial discipline. Maintaining a strong balance sheet remains a key priority as we execute our long-term strategy. During the quarter, we raised approximately $5 million through our ATM program, which continues to provide us with the balance sheet flexibility and liquidity to support our growth. Michael will discuss our balance sheet in more detail shortly. In summary, we made progress in the second quarter, and while our results reflect the expected variability of a turnaround being executed in a dynamic consumer environment, we entered the second half of the year a stronger company with the right strategy and team. Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was 12 months ago. Our focus for the balance of the year is unchanged. Convert the stabilization achieved year-to-date into sustained profitable growth. That means same-center sales, marketing efficiency, and consistent execution across our locations. We expect the actions underway to be reflected in our results in the quarters ahead. And with that, I will now pass it over to Michael. Michael Arthur: Thank you, Yogi. Good morning, everyone. As Yogi mentioned, we are pleased to deliver our second consecutive quarter of stable revenue. We continue to see encouraging signs across the business. Underlying case volume increased year-over-year. Our newer procedures continue to gain traction, and we remain focused on executing the strategic priorities Yogi outlined. Turning to the second quarter, revenue for the quarter was $42.9 million, a decrease of 2.5% versus the prior year quarter. On a same-center basis, excluding the impact of London, revenue declined approximately 1%, reflecting positive 1% case growth in the quarter, the second consecutive quarter of year-over-year case growth, a continued sign of stabilization. This was offset by a 2% decline in average selling price in the quarter. The decline in average selling price was primarily driven by our comparison against an unusually high average selling price in the prior year period. Average selling price for the quarter of approximately $12,700 remains well within our historical range. Cost of services was $16.6 million, resulting in gross margin expansion to roughly 61% of revenue. Selling, general and administrative expenses were approximately $23.4 million, an increase of approximately $750,000 compared to prior year. This reflects the deliberate choice to increase investment in marketing and brand development by $1.5 million in the quarter. This was offset by efficiencies in general and administrative expense. Customer acquisition cost for the quarter was roughly $3,500 per case, compared to approximately $2,900 in the prior year quarter. While elevated, as Yogi mentioned, we made intentional investments in brand marketing. While the spend is not fully optimized today, we do expect these investments to pay off in the future. Overall, cost disciplines continue to be a priority. And equally important is being strategic about where we reinvest those savings to drive long-term shareholder value. As a result, adjusted EBITDA was $4.9 million, roughly 11.5% of revenue, a decrease of $900,000 from the prior year. Through June 30, 2026, cash provided by operating activities after capital expenditures was approximately $3.8 million, up slightly year-over-year. Also, year-to-date, we raised roughly $20 million on our ATM and paid down debt of approximately $13 million. As it relates to our balance sheet, we ended the quarter with roughly $19 million in cash and $5 million available in our revolver, resulting in roughly $24 million of liquidity available to the company at the end of the quarter. Turning to our term loan, we ended the quarter with approximately $44 million of gross debt and remain in compliance with all covenants under our credit agreement. We recently signed an amendment extending the maturity of the facility to November 2027. At the same time, we continue to make progress refinancing. The continued stability in our business has allowed us to receive multiple term sheets that we believe are aligned with our long-term interests, and a maturity extension gives us additional time to achieve the right transaction. Now, turning to guidance. As you saw in our earnings release, we are reaffirming our outlook at the lower end of our revenue guidance and updating our adjusted EBITDA outlook to a range of $12 million to $14 million, which reflects our intentional investment and marketing of an additional $5 million this year to support future growth. We believe this will strengthen the business and support improving performance over time. Our guidance assumes a stable macroeconomic environment through the balance of the year and does not contemplate any further deterioration in consumer demand. While we are not providing quarterly guidance, we thought it would be helpful to provide context for our expectations in Q3 versus Q4. On a comparable basis, excluding London center sales from 2025, we expect third quarter revenue to be down single digits. In Q4, we expect continued ramp of our existing and new service offerings and market efforts to deliver year-over-year growth in revenue and adjusted EBITDA on a comparable basis. Additionally, while we're introducing new procedures such as AlloClae, our guidance does not include any contributions from these offerings given how early they are in the implementation process. While we remain mindful of the current environment, we continue to be encouraged by the underlying fundamentals of the business, including continued growth in case volume, progress of our strategic initiatives, and the early impact we're seeing from our expanded marketing efforts. We believe these investments position the business well for improving performance as we move through the remainder of the year. Importantly, we've made significant strides strengthening the business. In the past year alone, we have stabilized revenue trends, improved same-center sales from -23% in the first half of 2025 to flat year-to-date, reduced gross debt by over $30 million since the start of 2025, and increased cash by over $10 million since the start of 2025. Overall, the business is much stronger on almost all accounts compared to a year ago. As we look towards the second half of the year, we remain focused on disciplined execution, maintaining financial flexibility, and continuing to invest in initiatives we believe will drive long-term shareholder value. And with that, I'll turn it back to you, Yogi, for closing remarks. Yogesh Jashnani: Thank you, Michael. In closing, I want to thank our team for their hard work and dedication. The progress we described today is a direct result of their efforts. While we remain mindful of the current environment, we are building momentum across the business through disciplined execution. We remain confident in the opportunities ahead and our ability to deliver long-term shareholder value. With that, I'd like to turn the call over to the operator to begin the question-and-answer portion of the call. Operator: [Operator Instructions] Your first question comes from the line of Sam Eiber with BTIG. Sam Eiber: Maybe I can start on the market environment, Yogi, and the trends that you've seen in July and into August, and then your ability to maybe sustain procedure volume growth for the back half of the year. Yogesh Jashnani: Sam, this is Yogi. Thank you for the question. Thanks for joining. First of all, I'm really pleased with the stability we've been able to deliver for two consecutive quarters. Underlying case volume growth for sure. And just the continued traction from the new procedures that we have, we've been able to accelerate those as well as just the discipline across the company. You see that in the cost initiatives as well. As it relates to trends, we did see the trends soften in June from earlier in the quarter, and that continued into July. We attribute that to the fact that we're just executing a transformation in a choppy consumer environment, frankly, so that's what led us to make sure that we provide additional insight where we don't guide quarter to quarter. This time around, we wanted to provide additional insight on what to expect in Q3 and Q4. So we remain confident that what we have with what we're doing, the new services, the marketing, as well as just the disciplined execution will allow us to end the year with growth and at the low end of the guidance that we have provided at the beginning of the year in terms of revenue. Sam Eiber: Okay, that's really helpful. And maybe I can use a follow-up here on the AlloClae partnership. Maybe I can just get your thoughts on the strategic rationale there. Is this going after a separate patient demographic than your traditional core body contouring procedures? And then long-term, just the idea of AirSculpt maybe turning into what was formerly just a body contouring business into maybe a full service and suite of platforms that can offer patients different aesthetics needs. Yogesh Jashnani: Sam, great question. Thanks for that. I'll answer both parts of your question. On AlloClae, we view that as a complementary procedure to body contouring. So if you think about what AlloClae does, it's a great opportunity to provide and extend or really reach to patients who have body contouring needs, but do not have either enough fat to transfer or have other reasons why they would want to, you know, external fat rather than their own fat for transfer. So in the near term, it allows us to expand our reach to patients who we could not serve earlier. More broadly, it fits within our brand. It fits within what we do. It is body contouring, can be done in our facilities under local anesthesia. So as far as procedures are concerned, we think this is a great fit and expansion and complementary to fat transfers that we're doing. We are constantly looking at what procedures make sense for AirSculpt, what can we do within our four walls? And that pipeline is also very robust in what we are evaluating. So as far as are we looking to expand procedures, absolutely. The goal is how do we increase center productivity and drive same-store sales, we continue to do things which make sense and resonate with our patients. Operator: Your next question comes from the line of Whit Mayo with Leerink Partners. Please go ahead. Dean Rosales: This is Dean Rosales for Whit. We've heard commentary from the payer space expressing that some employers are dropping GLP-1 coverage intra-year. Have you experienced this potential headwind in your case volumes yet? And finally, how do you expect this would influence business in the mid and long term if GLP-1 uptake were to sort of moderate as payer dynamics shift? Yogesh Jashnani: Thank you for that question. So the short answer to what you're saying is, as employers are dropping coverage, we've not seen that have an impact or noticeable impact on our business. Broadly, the GLP-1 trend has been up and to the right in terms of adoption by consumers. And we see that in consumers coming to us as well. So the patients who are reaching out to us, who are doing the consultations, including increasing amounts of them are on GLP-1s. The new procedures are resonating with them. We're pleased with what we have and continue to expand over there. If it does create a bit of a hiccup for GLP-1 adoption, I think it would be well within, frankly, what would work for us in terms of being able to serve both people who have GLP-1 side effects and if people end up not going down the GLP-1 route and need traditional fat removal, fat transfer, then we can do that as well. Operator: Your next question comes from the line of Jonna Kim with Cowen and Company. Jungwon Kim: The first one is what evidence do you have that increased marketing spend is generating higher ROI for you and how do you just see your marketing strategy evolve over time? And second one, what KPIs do you monitor throughout the year and how are you reflecting on these KPIs real-time to make improvements? Yogesh Jashnani: Jonna, thank you so much for the questions. I'll answer it in the order you asked them. So as far as marketing investments are concerned, you think about marketing investments as if I'm investing a dollar today, over the life of that dollar, am I going to get more than a dollar back in terms of profit essentially. So that does a couple of things. We are not looking at just spending to the average, looking at every, you know, effectively every dollar and whether that's working hard for us or not. Some of those are done within the quarter and some of those would return outside the quarter. But effectively, that's how we are monitoring. That's how we are focusing on the ROI that's being generated. And currently, the results in many ways speak for themselves. We've had stability for two consecutive quarters with case growth. That's a trend change from where the business has been for multiple quarters, if not multiple years. So that's been, part of that has been the enhanced marketing strategy that we have put in place. Going forward, as we said, we're going to continue to invest. A lot of those investments are also going into the new services, which is working. We're seeing that show up in our numbers. We expect to get more efficient as we learn how to market to GLP-1 customers, as we learn what's the best way to drive value over there. So in future quarters, I completely expect that our marketing will get even more efficient. We are committed to making sure that we are driving growth within the organization. And that's where the marketing investments come in. Operator: Your next question comes from the line of Nick Sherwood with Maxim Group. Nicholas Sherwood: How long had the building in that AlloClae capability, how long did that process take from evaluating to implementing it? And then was this a direct response to some of the concerns of your customers who had been uptaking GLP-1s and are you serving customers who are taking GLP-1s to find out what procedures you should add to your portfolio? Yogesh Jashnani: Nick, this is Yogi. Thank you for those questions. Over the last year or so, I would say we have, if I can talk more broadly about how we are evaluating procedures, over the last year or so, we've done an outreach and understood what's the universe of body contouring procedures, what makes sense within what we're doing. So really started with patient needs. What are patients needing? Where can those needs be met better? And as part of that, we have a constant evaluation process where we're looking at different solutions. AlloClae was one which has been, even before it hit the market, it has been something that we've been talking to Tiger Aesthetics with. We have a deep relationship with them. We provide other services that they have as well. So this one is something which, just like other things, it's well thought out. We keep an eye on it, and when the time is right, which we feel is now, we look to bring that in. We start with a few locations and then expand it as we get learnings, as we understand how to market this, how to serve the patients better. And broadly, that's what we are doing. We're looking constantly for what's on the market, what makes sense. In this particular case, it fits the need. It solves a problem for the patient, which is I don't have enough factory transfer. We do hear it, and we hear it increasingly from our patients. So that's a little bit of insight on how we go about these medical advisory board, which also advises us on these along the way. Nicholas Sherwood: And then thinking about some of the new marketing spend, how are you adapting, how are you evaluating and adapting that spending strategy across the quarters? What kind of KPIs are you bringing in real time? And then how are you also responding to that new sort of AI search landscape where, you know, click-through rates are really low on Google right now, and how are you making sure that you're getting potential customers onto your website? Yogesh Jashnani: Nick, thanks for that. As far as how we are doing marketing spending across the quarters and the KPIs, we covered some of this in Jonna's question as well. We take an approach of for every dollar that we're putting in, what's the expected return over the life of that dollar? And is that driving profitability. As it relates to new procedures, what we are seeing is how we reach out to GLP-1 patients. We're testing different channels, different messaging, different creatives, different landing pages. So it's a heavy test and learn approach that we are taking, both in the channels which we are present in and in new forums as well. That's the plan. We're committed to it because we see the need, we see the demand from patients. Now it's up to us to crack the code on how do we have an efficient outreach to them so that they allow us to serve their needs. The AI search landscape, like any direct-to-consumer marketer will tell you, that is definitely having an impact. I'm glad we're able to maintain stability and drive results despite a choppy consumer environment and despite AI search overviews creating headwinds as far as clicks are concerned. That's an evolving area. We continue to invest in how we show up when these search engines or when the LLMs are being turned to, whether it's Google, whether it's OpenAI, whether it's Claude. So that's one area. The other area is also where they don't have reach currently. Never say never, but things where people are looking for guidance, whether it's ratings, reviews, conversations. Also, how do you make sure that our presence over there is robust is the other way we're looking to beat the system. So there's more around how we show up well in AI and then when people are not turning to AI, but turning to other people, how do we show up well over there as well. Operator: Your next question comes from the line of Kyle Bauser with Titan Partners. Kyle Bauser: Maybe could you talk a little bit more about some of the newer procedures that you talked about in the past, like standalone skin tightening and skin removal? And you mentioned more today on the call. How many of the 31 centers are conducting these, and how does that economics or margins kind of compare with the existing services? Yogesh Jashnani: Kyle, I'll bucket it into three groups, essentially. We do skin tightening, which is your, as the name suggests, you're going in just slightly underneath the skin, tightening it. We do it either as standalone, or in most cases, actually, along with fat removal and fat transfers. That's available in all of our centers. The second bucket would be skin removal or skin excisions. There is four or five body areas where we do skin removal, skin excisions. Those are roughly in, I would say, 20 out of 30 locations or so, 20 out of the 31 locations that we have. That number continues to go up and certain procedures are in some locations. It all depends upon surgeon availability, surgeon preference, and we're working with our surgeons to expand that further. The third bucket is AlloClae, which we just announced on the call today. That's going into pilot later this quarter. So our first centers will start treating patients with AlloClae sometime later this quarter. As far as the economics are concerned, skin tightening and skin removal, the gross margin profile and the economics of that are very similar to our core fat removal, fat transfer business. So roughly a gross margin of 60-ish percent, which has been ticking up of late, if you might have noticed. So that we continue to expect to have a similar gross margin profile. Now, many of these are combined with other procedures. So the average ticket ends up being higher. So while we do have some patients who are doing standalone skin tightening, for example, most are combining it with either fat removal or fat removal and fat transfer. So anytime it's an add-on, we see the ticket price is higher for those. Same dynamic on skin removal as well. It's too early to know how AlloClae would work. Once we have it in our clinics, we have more insights. AlloClae does have a product cost. So the gross margin profile over there would be different. Gross margin percentage would be lower. The expectation is that the gross margin dollars would go higher so that net it's accretive to the business on a dollar perspective. Kyle Bauser: Got it. Appreciate that. And you mentioned, you know, the marketing to become a bit more efficient as you learn how to better market to GLP-1 patients moving forward. I think the customer acquisition cost is about, you mentioned $3,500, pretty similar with the last couple of quarters, maybe a slight step up. How should we anticipate the customer acquisition costs trending over the balance of the year based on investments you're making in marketing? Michael Arthur: Hey, this is Michael. Yes, I can take that one. Yes, so as you alluded to, CAC was approximately $3,500 in the quarter, which was up roughly relative to Q2 of last year, which was $2,900 a year ago. So it's a consistent step up in marketing investment as we discussed. A meaningful portion of that spend is top of the funnel brand building investments that don't necessarily show up in this quarter's case volume, but over time, it's designed to lower CAC as we expand our reach, improving lead quality and the like. And so as case volume builds and these investments mature, we do expect CAC to come down and marketing to turn back towards our lower percentage of revenue as well. It's another way we look at it, which, you know, last year was around 18% and year-to-date we've been around 20% of revenue. Operator: This now concludes our question and answer session. I would like to turn the floor back over to management for closing comments. Yogesh Jashnani: Thank you everyone for joining us for our second quarter earnings call. We look forward to connecting with many of you at investor events over the next few days and weeks, and then also report back on our third quarter in a few months. Thank you. Operator: Ladies and gentlemen, thank you for your participation. This does conclude today's teleconference. You may disconnect your lines and have a wonderful day. Before you buy stock in AirSculpt Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AirSculpt Technologies wasn’t one of them. The 10 stocks that made the cut are built for long-term growth and could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,511!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,381,960!* That performance is why people listen. With a track record of beating the S&P 500 by nearly 5x, Stock Advisor offers a distinct advantage. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built for the long haul. See the 10 stocks » *Stock Advisor returns as of August 17, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. AirSculpt (AIRS) Q2 2026 Earnings Call Transcript was originally published by The Motley Fool

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results that showed slightly lower sales and a wider net loss, while management reaffirmed full year revenue guidance at the lower end of its range. See our latest analysis for AirSculpt Technologies. The Q2 2026 earnings release and reaffirmed revenue outlook have landed after a period of sharp share price swings for AirSculpt Technologies, with the stock up strongly year to date but total shareholder return over the past year still significantly negative. This points to fading momentum despite the latest move. If this kind of volatility has you looking beyond a single healthcare stock, it could be a good moment to broaden your watchlist with 43 healthcare AI stocks AirSculpt Technologies is trying to prove its body contouring model can support steady revenue while still posting losses and sharp share price swings. After this rebound, does the current valuation fairly reflect that trade off or overshoot it? Analyst consensus implies a fair value of $4.50 for AirSculpt Technologies compared with the recent close around $3.25, which puts the narrative valuation well ahead of the market price and sets up a clear gap to examine. Read the complete narrative. Want to see what this narrative is really baking in? It leans on steady revenue build, higher margins and a punchy future earnings multiple. Curious how those pieces fit together. Result: Fair Value of $4.50 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, AirSculpt Technologies still faces pressure from weaker discretionary spending and higher customer acquisition costs, which could keep procedure volumes and margins under strain. Find out about the key risks to this AirSculpt Technologies narrative. The analyst narrative points to a fair value of $4.50, yet the P/S ratios tell a different story. AirSculpt Technologies trades at 1.6x sales, above the US Healthcare sector at 1.4x and its own fair ratio of 1.3x. That gap suggests investors are already paying up. Does that leave much cushion if expectations change? For a closer look at what the numbers imply about upside and downside risk on the current price tag, See what the numbers say about this price — find out in our valuation breakdown. With sentiment on AirSculpt Technologies clearly mixed, this is a good moment to move quickly and test the data for yourself rather than rely on headlines. To understand the specific issues that investors are watching, check the 3 important warning signs. If AirSculpt Technologies has you thinking harder about where to put fresh capital, do not stop here. Use the Simply Wall St screener to surface new opportunities before they slip past. Target higher quality potential by focusing on companies that look mispriced on fundamentals with the screener containing 20 high quality undiscovered gems. Strengthen your core holdings with businesses that pair financial resilience and cleaner balance sheets through the solid balance sheet and fundamentals stocks screener (49 results). Prioritize stability and capital preservation by filtering for companies with lower assessed risk using the 85 resilient stocks with low risk scores. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIRS. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

This article first appeared on GuruFocus. Revenue: $42.9 million, a decrease of 2.5% versus the prior year quarter. Same-Center Revenue: Declined approximately 1% on a same-center basis, excluding the impact of London. Case Growth: Positive 1% case growth in the quarter, the second consecutive quarter of year-over-year case growth. Average Selling Price: Approximately $12,700, a 2% decline primarily driven by comparison against an unusually high prior year period. Gross Margin: Expanded to roughly 61% of revenue, with cost of services at $16.6 million. SG&A Expenses: Approximately $23.4 million, an increase of about $750,000 compared to prior year, reflecting a $1.5 million increase in marketing and brand development investment. Customer Acquisition Cost: Roughly $3,500 per case, compared to approximately $2,900 in the prior year quarter. Adjusted EBITDA: $4.9 million, roughly 11.5% of revenue, a decrease of $900,000 from the prior year. Cash Flow: Cash provided by operating activities after capital expenditures was approximately $3.8 million through June 30, 2026, up slightly year over year. Balance Sheet: Ended the quarter with roughly $19 million in cash and $5 million available in the revolver, totaling approximately $24 million in liquidity. Debt: Approximately $44 million of gross debt at the end of the quarter; raised roughly $20 million on ATM and paid down debt of approximately $13 million year-to-date. Guidance: Reaffirmed revenue outlook at the lower end and updated adjusted EBITDA outlook to a range of $12 million to $14 million, reflecting an intentional additional $5 million investment in marketing this year. Warning! GuruFocus has detected 3 Warning Signs with AIRS. Is AIRS fairly valued? Test your thesis with our free DCF calculator. Release Date: August 10, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AirSculpt Technologies Inc (NASDAQ:AIRS) delivered its second consecutive quarter of stable revenue and positive same-center case growth, indicating business stabilization. The company is expanding its procedure portfolio with new offerings like skin excision, upper blepharoplasty, mastopexy, and the AlloClae partnership, targeting the growing GLP-1 patient market. Gross margin expanded to approximately 61% of revenue, reflecting improved cost discipline and operational efficiency. The company strengthened its balance sheet by reducing gross debt by over $30 million since the start of 2025 and increasing cash by over $10 million, with liquidity of $24 million at quarter-end. Management reaffirmed its revenue guidance and expects Q4 to deliver year-over-year growth in revenue and adjusted EBITDA on a comparable basis, driven by new services and marketing efforts. Revenue declined 2.5% year-over-year in Q2, and same-center revenue was down approximately 1%, reflecting ongoing challenges in a dynamic consumer environment. Sales trends softened in June and continued into July, attributed to a choppy consumer environment, leading to a cautious outlook for Q3 with revenue expected to be down single digits. Customer acquisition cost increased to approximately $3,500 per case from $2,900 in the prior year, driven by intentional but not yet optimized marketing investments. Adjusted EBITDA decreased by $900,000 to $4.9 million, and the company updated its full-year adjusted EBITDA guidance to a lower range of $12 million to $14 million. The company faces headwinds from AI search overviews reducing click-through rates, requiring ongoing adaptation in marketing strategies to maintain lead generation. Q: What evidence do you have that increased marketing spend is generating higher ROI, and how do you see your marketing strategy evolve over time? What KPIs do you monitor throughout the year and how are you reflecting on these KPIs real-time to make improvements?A: Yogesh Jashnani (CEO): We evaluate marketing investments by assessing whether each dollar invested will generate more than a dollar back in profit over its lifetime. We are not just spending to the average; we are scrutinizing every dollar to ensure it's working hard. The results speak for themselves, as we've achieved stability for two consecutive quarters with case growth, a trend change from prior years. Going forward, we will continue to invest, particularly in new services, and expect to become more efficient as we learn how to market to GLP-1 customers. We are committed to driving growth and ensuring our marketing investments become more efficient in future quarters. Q: Can you talk about the market environment and trends seen in July and into August, and your ability to sustain procedure volume growth for the back half of the year?A: Yogesh Jashnani (CEO): We are pleased with the stability delivered for two consecutive quarters, with underlying case volume growth and continued traction from new procedures. However, we did see trends soften in June from earlier in the quarter, and that continued into July, which we attribute to executing a transformation in a choppy consumer environment. This led us to provide additional insight on Q3 and Q4 expectations. We remain confident that our new services, marketing efforts, and disciplined execution will allow us to end the year with growth and at the low end of our initial revenue guidance. Q: What is the strategic rationale behind the AlloClae partnership? Is this going after a separate patient demographic than your traditional core body contouring procedures? And long-term, is AirSculpt turning into a full-service platform offering patients different aesthetic needs?A: Yogesh Jashnani (CEO): AlloClae is a complementary procedure to body contouring. It allows us to reach patients who have body contouring needs but do not have enough fat for a traditional fat transfer. In the near term, it expands our reach to patients we could not serve earlier. More broadly, it fits within our brand and can be done in our facilities under local anesthesia. We are constantly evaluating procedures that make sense for AirSculpt to increase center productivity and drive same-store sales. The pipeline of procedures we are evaluating is robust, and we are absolutely looking to expand our offerings. Q: We've heard commentary that some employers are dropping GLP-1 coverage intra-year. Have you experienced this potential headwind in your case volumes yet? How would this influence business if GLP-1 uptake were to moderate as payer dynamics shift?A: Yogesh Jashnani (CEO): We have not seen a noticeable impact on our business from employers dropping GLP-1 coverage. The GLP-1 trend has been up and to the right in terms of consumer adoption, and we see that in the increasing number of patients on GLP-1s reaching out to us. If there is a hiccup in GLP-1 adoption, we are well-positioned to serve both people who have GLP-1 side effects and those who need traditional fat removal or fat transfer. Q: How long did the process take from evaluating to implementing the AlloClae capability? Was this a direct response to concerns of customers who had been uptaking GLP-1s, and are you serving customers on GLP-1s to find out what procedures to add to your portfolio?A: Yogesh Jashnani (CEO): Over the last year or so, we've done outreach to understand the universe of body contouring procedures and what makes sense within our operations. We started with patient needs and have a constant evaluation process. AlloClae was something we've been discussing with Tiger Aesthetics for a while, given our deep relationship. We start with a few locations and expand as we gain learnings. We hear from patients increasingly that they don't have enough fat for a transfer, and this procedure solves that problem. Our medical advisory board also advises us on these decisions. Q: How are you adapting and evaluating your marketing spending strategy across the quarters? What KPIs are you bringing in real-time, and how are you responding to the new AI search landscape where click-through rates are low on Google?A: Yogesh Jashnani (CEO): We take an approach of evaluating the expected return on every dollar invested over its life. For new procedures, we are testing different channels, messaging, creatives, and landing pages to reach GLP-1 patients. It's a heavy test-and-learn approach. The AI search landscape is definitely having an impact, like any direct-to-consumer marketer. We are investing in how we show up in AI search engines like Google, OpenAI, and Claude, and also ensuring our presence is robust in other areas where people seek guidance, such as ratings and reviews. Q: Could you talk more about the newer procedures like standalone skin tightening and skin removal? How many of the 31 centers are conducting these, and how does the economics or margins compare with existing services?A: Yogesh Jashnani (CEO): We bucket these into three groups. Skin tightening is available in all centers, often combined with fat removal and fat transfers. Skin removal or skin excisions are in roughly 20 out of 31 locations, with that number continuing to grow based on surgeon availability and preference. AlloClae is going into pilot later this quarter. The gross margin profile for skin tightening and skin removal is very similar to our core business, around 60%. When combined with other procedures, the average ticket is higher. For AlloClae, the gross margin percentage will be lower due to product costs, but we expect gross margin dollars to be higher, making it accretive on a dollar perspective. Q: How should we anticipate customer acquisition costs (CAC) trending over the balance of the year based on the investments you're making in marketing?A: Michael Arthur (CFO): CAC was approximately $3,500 in the quarter, up from $2,900 in the prior year quarter. A meaningful portion of the increased spend is top-of-funnel brand building investments that don't necessarily show up in this quarter's case volume but are designed to lower CAC over time by expanding reach and improving lead quality. As case volume builds and these investments mature, we expect CAC to come down and marketing to return to a lower percentage of revenue, which was around 18% last year and around 20% year-to-date For the complete transcript of the earnings call, please refer to the full earnings call transcript.

AirSculpt Technologies reported past second-quarter 2026 results showing sales of US$42.9 million versus US$44.01 million a year earlier and a wider net loss of US$1.11 million, while six-month sales slipped to US$82.29 million with a modestly higher cumulative net loss of US$3.51 million. Despite the softer top line and continued losses, the company reaffirmed its full-year 2026 revenue outlook at the lower end of its US$151 million to US$157 million guidance range, signaling management’s commitment to its existing operating plan. We will now examine how reaffirming full-year revenue guidance, despite slightly weaker quarterly results, affects AirSculpt’s existing investment narrative. Uncover the next big thing with 20 elite penny stocks that balance risk and reward. To own AirSculpt Technologies, you need to believe its niche in minimally invasive body contouring and GLP-1 related procedures can eventually offset ongoing losses and a volatile demand backdrop. The latest quarter’s slightly weaker sales and wider net loss do not materially change that big picture, but they do keep the main near term catalyst and risk squarely in focus: stabilizing procedure volumes while managing marketing spend and leverage. The most relevant recent announcement is AirSculpt’s decision to reaffirm its full year 2026 revenue outlook at the lower end of its US$151 million to US$157 million range, even after softer Q2 results. For me, that ties directly to the core catalyst of gradually improving case volumes and procedure mix, while also highlighting the risk that any further macro or consumer softness could make hitting even the low end of guidance more challenging. Yet behind that guidance, investors should be aware that rising acquisition costs and ongoing net losses could still... Read the full narrative on AirSculpt Technologies (it's free!) AirSculpt Technologies' narrative projects $161.9 million revenue and $9.9 million earnings by 2029. This requires 2.2% yearly revenue growth and a $21.1 million earnings increase from -$11.2 million today. Uncover how AirSculpt Technologies' forecasts yield a $6.25 fair value, a 94% upside to its current price. Before this Q2 update, the most optimistic analysts were banking on revenue reaching about US$165.5 million and earnings of roughly US$2.7 million, a far brighter path than the consensus narrative and one that leaned heavily on GLP-1 driven demand and new procedures scaling well, which this latest quarter may prompt you to reassess. Explore 2 other fair value estimates on AirSculpt Technologies - why the stock might be worth less than half the current price! Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. A great starting point for your AirSculpt Technologies research is our analysis highlighting 3 important warning signs that could impact your investment decision. Our free AirSculpt Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AirSculpt Technologies' overall financial health at a glance. Every day counts. These free picks are already gaining attention. See them before the crowd does: Find 51 companies with promising cash flow potential yet trading below their fair value. The latest GPUs need a type of rare earth metal called Neodymium and there are only 28 companies in the world exploring or producing it. Find the list for free. Outshine the giants: these 16 early-stage AI stocks could fund your retirement. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include AIRS. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Same Center Cases Up 1% for the Second Consecutive Quarter MIAMI BEACH, Fla., Aug. 10, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the second quarter ended June 30, 2026. Yogi Jashnani, Chief Executive Officer, stated: “In the second quarter, we advanced our key priorities — delivering our second quarter of stability. During the quarter, we stepped up our investment in marketing and advanced our plans to introduce new, sought-after procedures including entering an exclusive partnership with AlloClae that expands our treatment offering and enhances our body contouring platform.” “We enter the second half of the year a fundamentally stronger company with the right strategy and team. Our addressable market is larger, our procedure mix is broader, and our operating platform is more disciplined than it was twelve months ago,” concluded Mr. Jashnani. Second Quarter and First Six Months 2026 (“YTD”) Highlights Positive Business Momentum: Advanced Strategic Priorities: Second Quarter 2026 Results Case volume was 3,376 for the second quarter of 2026, representing a (0.5)% decrease from the fiscal year 2025 second quarter case volume of 3,392 Revenue declined (3)% to $42.9 million from $44.0 million in the fiscal year 2025; Net loss for the quarter was $1.1 million compared to net loss of $0.6 million in the fiscal year 2025 second quarter; and Adjusted EBITDA was $4.9 million compared to $5.8 million in the fiscal year 2025 second quarter. First Six Months 2026 Results Case volume was 6,458 for the first six months of 2026, representing a (0.2)% decrease from the first six months of 2025 case volume of 6,468 Revenue declined 1.3% to $82.3 million from $83.4 million in the first six months of fiscal year 2025; Net loss was $3.5 million compared to $3.4 million in the first six months of fiscal year 2025; and Adjusted EBITDA was $8.2 million compared to $9.6 million in the first six months of fiscal year 2025. 2026 Outlook The Company is reaffirming its full year 2026 revenue at the lower end of its guidance range of approximately $151 to $157 million and reducing its adjusted EBITDA outlook to the range of approximately $12 to $14 million. For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below. Debt & Liquidity As of June 30, 2026, the Company had $18.8 million in cash and cash equivalents, with $5.0 million of borrowing capacity under its revolving credit facility. Additionally, gross debt was approximately $44.2 million. During the 2026 second quarter, the Company raised an additional $5.0 million from the at-the-market offering program and paid down $1.4 million of debt. On August 7, 2026, the Company entered into an amended term loan agreement that extends its maturity to November 2027. In connection with the amendment, the Company made a $2.5 million term loan payment at signing and is required to make an additional $2.5 million payment on or before September 30, 2026. The Amendment also requires that 50% of the net proceeds of future equity issuances (other than under the Company's equity incentive plans) be applied to prepay the term loans. Conference Call Information AirSculpt will hold a conference call today, August 10, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13761751 or by visiting the link below to request a return call for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6 The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call. To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible. About AirSculpt AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K. Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest. The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release. There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Use of Non-GAAP Financial Measures The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Comparable Net Revenue, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results. These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP. AirSculpt Technologies, Inc. and SubsidiariesReconciliation of Non-GAAP Financial Measures(Dollars in thousands) We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. We define Adjusted EBITDA as net loss excluding depreciation and amortization, net interest expense, income tax benefit, restructuring and related severance costs, certain other non-recurring costs, unrealized (gain)/loss, and equity-based compensation. We define Adjusted Net Loss as net loss excluding restructuring and related severance costs, certain other non-recurring costs, equity-based compensation and the tax effect of these adjustments. We include Adjusted EBITDA and Adjusted Net Loss because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Loss each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Loss has limitations as an analytical tool because it does not include results from equity-based compensation. We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Loss per Share as Adjusted Net Loss divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Loss per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Loss per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net loss, the most directly comparable GAAP financial measure: The following table reconciles Adjusted Net Loss and Adjusted Net Loss per Share to net loss, the most directly comparable GAAP financial measure: Investor ContactAllison MalkinICR, [email protected]

Interested in AirSculpt Technologies, Inc.? Here are five stocks we like better. Q2 revenue fell 2.5% to $42.9 million, while same-center cases grew 1% year over year but were offset by a 2% decline in average selling price. Adjusted EBITDA decreased to $4.9 million as the company increased marketing spending. AirSculpt is expanding beyond core fat-removal procedures to capture demand from GLP-1 users, adding skin excision, breast procedures and the planned rollout of alloClae. Management estimates expanded services could generate more than $100 million in long-term revenue across its existing centers. The company raised about $5 million in equity during the quarter and ended with approximately $24 million in liquidity, while reducing debt. AirSculpt reaffirmed its revenue outlook, lowered its 2026 adjusted EBITDA target to $12 million-$14 million due to additional marketing investment, and expects comparable revenue to decline in Q3 before improving in Q4. AirSculpt Technologies (NASDAQ:AIRS) reported second-quarter revenue of $42.9 million, down 2.5% from the prior-year period, as the company cited stable revenue trends, positive same-center case growth and continued investment in marketing and expanded procedure offerings. Chief Executive Officer Yogi Jashnani said the company’s transformation efforts have contributed to improving sales comparisons. Same-center sales improved by 21 percentage points from the second quarter of 2025 and by 23 percentage points year to date, he said. On a comparable basis, the company recorded roughly flat same-center sales growth in the first half of 2026. → MarketBeat Week in Review – 08/03 - 08/07 “Our near-term focus remains squarely on increasing same-center sales,” Jashnani said, while adding that the company sees longer-term growth opportunities in new procedures and future de novo center expansion as its balance sheet and cash generation improve. Chief Financial Officer Michael Arthur said second-quarter same-center revenue, excluding the impact of the London location, declined approximately 1% from a year earlier. That result reflected 1% same-center case growth, the company’s second consecutive quarter of year-over-year case growth, offset by a 2% decline in average selling price. → Quantum Earnings Week: Winners and Losers Are Finally Emerging Average selling price was about $12,700 during the quarter, which Arthur said remained within the company’s historical range. He attributed the year-over-year decline principally to comparison with an unusually high average selling price in the prior-year quarter. Cost of services was $16.6 million, resulting in gross margin of roughly 61% of revenue. Selling, general and administrative expenses rose by about $750,000 year over year to approximately $23.4 million, driven by a deliberate $1.5 million increase in marketing and brand-development spending, partially offset by general and administrative efficiencies. → Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War Customer acquisition cost increased to roughly $3,500 per case from approximately $2,900 in the prior-year period. Arthur said the higher expense reflected intentional investments in brand marketing, which management expects to support future returns even though the spending is not fully optimized currently. Adjusted EBITDA totaled $4.9 million, or roughly 11.5% of revenue, down $900,000 from a year earlier. Cash provided by operating activities after capital expenditures was approximately $3.8 million through June 30, slightly above the prior-year period. Management continued to emphasize the potential opportunity among patients using GLP-1 medications. Jashnani said the company estimates that nearly 19 million potential patients may be interested over time in body contouring or related aesthetic procedures. During the quarter, AirSculpt completed more than 200 skin excision procedures and expanded that service to additional centers. The company also broadened its offerings to include upper breastoplasty and mastopexy. Jashnani said expanded procedures could represent a long-term revenue opportunity of more than $100 million across the existing center base, with additional potential if the company resumes de novo expansion. The company also announced a partnership with Tiger Aesthetics to offer alloClae, a structural adipose tissue allograft used for nonsurgical body contouring and targeted volume restoration. The offering is expected to begin rolling out to select centers later in the third quarter. Jashnani said alloClae could help AirSculpt serve patients who do not have enough fat for a traditional fat transfer or prefer an external-fat option. He added that the procedure fits the company’s body-contouring focus and can be performed in its facilities under local anesthesia. In response to an analyst question, Jashnani said skin tightening is available at all of the company’s centers, while skin excision procedures are offered at roughly 20 of its 31 locations. Management said the gross-margin profile for skin tightening and skin removal is generally similar to its core fat-removal and fat-transfer business, at approximately 60%. alloClae is expected to carry a lower gross-margin percentage because of product costs, though management expects it to be accretive on a gross-margin-dollar basis. AirSculpt raised approximately $5 million through its at-the-market equity program during the quarter. Year to date, the company raised roughly $20 million through the program and repaid approximately $13 million in debt. At quarter end, the company had about $19 million in cash and $5 million available on its revolving credit facility, for approximately $24 million of available liquidity. Gross debt stood at about $44 million. Arthur said AirSculpt remained in compliance with its credit covenants and recently amended its term loan to extend the facility’s maturity to November 2027. Arthur said the company has received multiple refinancing term sheets and continues to work toward a transaction it believes aligns with its long-term interests. The company reaffirmed its revenue outlook at the lower end of its previously provided range and updated its adjusted EBITDA outlook to $12 million to $14 million. The revised EBITDA outlook reflects an additional $5 million of marketing investment planned for 2026. Management expects comparable third-quarter revenue, excluding 2025 London center sales, to decline by a single-digit percentage. For the fourth quarter, AirSculpt expects expanded service offerings and marketing efforts to contribute to year-over-year growth in comparable revenue and adjusted EBITDA. The outlook assumes a stable macroeconomic environment and no further deterioration in consumer demand. Jashnani said sales trends softened in June and continued into July amid what he described as a “choppy consumer environment.” Still, he said management expects new services, marketing initiatives and operating discipline to support growth by year end. AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction. Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. The article "AirSculpt Technologies Q2 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for August 2026.

Interested in AirSculpt Technologies, Inc.? Here are five stocks we like better. AirSculpt reported a Q1 operational inflection: revenue of $39.4M was flat year‑over‑year with the first positive same‑center sales in over two years, gross margin expanded to roughly 60%, and adjusted EBITDA was $3.3M (~8.4% of revenue). Management attributed the improvement to stronger marketing and sales execution — expanded media mix, CTV, influencer engagement and digital‑funnel upgrades — which drove higher case volumes and a 19% sequential same‑store revenue improvement, though customer acquisition cost rose to about $3,400 per case. The balance sheet strengthened as the company ended the quarter with roughly $16.7M in cash, paid down $11M of debt (gross debt ~ $46M, leverage below 2.5x), is pursuing a term‑loan refinance, reaffirmed full‑year guidance, and does not plan any de novos in 2026. AirSculpt Technologies (NASDAQ:AIRS) reported first-quarter fiscal 2026 results that management characterized as a “key turning point,” citing stabilized revenue, the first positive same-center sales result in more than two years, and continued debt reduction. Chief Executive Officer Yogi Jashnani said the company “stabilized revenue year-over-year and delivered positive same-center sales for the first time in over two years,” while also expanding gross margin. Chief Financial Officer Michael Arthur reported revenue of $39.4 million for the quarter, “flat versus the prior year quarter and up 1% on a same-store basis, excluding the impact of London.” Arthur added that same-store revenue growth was driven by higher case volume and represented “a 19% sequential improvement.” → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Cost of services was $15.6 million, which Arthur said resulted in “gross margin expansion of roughly 1% to 60% of revenue.” Adjusted EBITDA was $3.3 million, or “roughly 8.4% of revenue,” down from 9.5% in the prior-year period. Management emphasized that marketing and sales execution improvements are translating into more consistent demand. Jashnani pointed to initiatives launched at the end of 2025, including an expanded media mix and improvements to the company’s digital funnel. He said the company continues to see benefits from “Connected TV, increased influencer engagement, and more targeted campaigns across skin tightening and skin removal,” and added that “improvements to our digital funnel and website are driving higher quality leads and better conversion.” → Light Speed Returns: Corning Cashes In on NVIDIA Growth On the Q&A portion of the call, BTIG analyst Sam Eiber asked what has been working in the quarter and how much improvement was attributable to marketing, new services, or a better demand environment. Jashnani said the company could tie the improvement “directly to the enhancements to sales and marketing and all of the foundational work we did in 2025,” adding that the consumer environment “is still I would say challenging, especially for considered purchases.” Arthur said selling, general and administrative expenses were approximately $22.6 million, up about $800,000 from the prior year, reflecting “a deliberate choice to increase investment in marketing and brand development.” He also disclosed that customer acquisition cost was “roughly $3,400 per case,” compared with $3,130 in the prior-year quarter. → Years in the Making, AMD’s Upside Movement Has Just Begun Jashnani spent part of his prepared remarks outlining how GLP-1 medications are influencing the aesthetics market and how AirSculpt is positioning its offering. He said GLP-1 medications “continue to fundamentally reshape the aesthetics landscape,” and cited expectations that the GLP-1 user base could grow from approximately 5 million in 2023 to 25 million by 2030. Jashnani also referenced an estimate that 63% of those patients indicate interest in treatment, which he said could translate to “nearly 19 million potential patients pursuing body contouring or related procedures.” He said the company’s minimally invasive procedures and limited downtime align with these patients’ needs, and highlighted newer services such as standalone skin tightening and skin removal. Jashnani noted that these offerings are intended to address side effects from GLP-1 use and help patients achieve their desired look. While he said traction is growing, management emphasized that these newer procedures are not yet a meaningful driver of results. Jashnani disclosed the company completed “over 150 skin excision procedures in Q1 alone,” and said that combined with fat removal and fat transfer, these procedures “have the potential to unlock more than $100 million in long-term revenue across our existing centers.” In response to Eiber’s question, Jashnani added that skin removals “are still in pilot phase and being rolled out across centers, so they've not been a meaningful incremental contributor yet.” Management also highlighted balance sheet progress. Jashnani said the company ended the quarter with “over $16 million in cash and leverage below 2.5x,” representing a reduction of more than one turn compared to the same time last year. Arthur provided additional details, stating that as of March 31, 2026, cash totaled $16.7 million and the company “paid down $11 million of debt in the quarter,” ending with gross debt of approximately $46 million. Arthur said AirSculpt is in compliance with all credit agreement covenants and is “making progress to refinance our term loan,” with an update expected when the company reports second-quarter results. He also reported cash flow from operations of approximately $5 million, compared with about $1 million in 2025. Arthur reaffirmed full-year fiscal 2026 guidance, calling for revenue of $151 million to $157 million and adjusted EBITDA of $15 million to $17 million. He said the midpoint of the revenue range implies “approximately 3% comparable growth excluding London from 2025,” and reminded listeners that the London center contributed 1% to comps in 2025. He also stated that guidance “does not contemplate any de novos in the period.” For the second quarter, which management described as seasonally stronger, Arthur said the company expects “sequential improvement in both revenue and EBITDA in absolute $ versus Q1.” Jashnani similarly said the company is targeting “sequential improvement in same-store sales” in the second quarter. During Q&A, Eiber asked whether a strengthened balance sheet could lead to reopening de novo center development later in the year. Arthur said the plan “doesn't contemplate any de novos in 2026,” and added the company remains focused on improving same-center sales growth as its “number one priority.” Looking ahead, Arthur said the company continues to monitor the macro environment, including consumer sentiment, and will remain “agile in managing the business as conditions evolve.” Jashnani closed by saying the company is “pleased with our start to 2026” and remains focused on building momentum to generate “long-term sustainable, profitable growth and value creation for our shareholders.” AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction. Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes. The article "AirSculpt Technologies Q1 Earnings Call Highlights" was originally published by MarketBeat. View MarketBeat's top stocks for May 2026.

Same Center Sales Increase 1% and Reaffirms Fiscal Year 2026 Outlook MIAMI BEACH, Fla., May 08, 2026 (GLOBE NEWSWIRE) -- AirSculpt Technologies, Inc. (NASDAQ:AIRS)(“AirSculpt” or the “Company”), a national provider of premium body contouring procedures, today announced results for the first quarter ended March 31, 2026. Yogi Jashnani, Chief Executive Officer, stated: “We had a solid start to the year delivering stabilization in revenue, positive same center sales, and a strengthened balance sheet in the first quarter. Our performance marks a key turning point for AirSculpt - the culmination of our transformational work in 2025 has given us a durable business model and a solid foundation to advance our strategy to achieve sustained long term profitable growth. I am proud of our team and confident in our ability to continue our favorable momentum as reflected in our reaffirmation of 2026 guidance.” "Same center sales continue to build as we enter our seasonally strong second quarter fueled by our enhanced and elevated sales and marketing initiatives,” continued Mr. Jashnani. “We move forward with the right talent, business model, strategy and balance sheet to maximize the power of our AirSculpt brand and proven body contouring procedures while broadening our reach, adding new incremental surgeries that leverage our operating platform and more fully capitalize on our GLP-1 opportunity. We believe that fiscal 2026 will include significant progress toward our goals of consistent revenue and profit growth and shareholder value creation,” concluded Mr. Jashnani. First Quarter 2026 Results Case volume was 3,082 for the first quarter of 2026, representing a 0.2% increase from the fiscal year 2025 first quarter case volume of 3,076; Revenue was flat at $39.4 million with the fiscal year 2025 first quarter and increased 1% on a same center sales basis; Net loss for the quarter was $2.4 million compared to net loss of $2.8 million in the fiscal year 2025 first quarter; and Adjusted EBITDA was $3.3 million compared to $3.8 million in the fiscal year 2025 first quarter. 2026 Outlook The Company is affirming its full year 2026 revenue and adjusted EBITDA guidance as follows: Revenue of approximately $151 to $157 million Adjusted EBITDA of approximately $15 to $17 million For additional information on forward-looking statements, see the section titled "Forward-Looking Statements" below. Debt & Liquidity As of March 31, 2026, the Company had $16.7 million in cash and cash equivalents, with $5.0 million of borrowing capacity under its revolving credit facility. Additionally, gross debt was approximately $45.6 million. During the 2026 first quarter, the Company raised an additional $14.6 million from the at-the-market offering program and paid down $11.4 million of debt. The Company remains in compliance with all debt covenants. Conference Call Information AirSculpt will hold a conference call today, May 8, 2026 at 8:30 am (Eastern Time). The conference call can be accessed by dialing 1-877-407-9716 (toll-free domestic) or 1-201-493-6779 (international) using the conference ID 13760143 or by visiting the link below to request a return call for instant telephone access to the event. https://callme.viavid.com/viavid/?callme=true&passcode=13725116&h=true&info=company&r=true&B=6 The live webcast may be accessed via the investor relations section of the AirSculpt Technologies website at https://investors.airsculpt.com. A replay of the webcast will be available for approximately 90 days following the call. To learn more about AirSculpt, please visit the Company's website at https://investors.airsculpt.com. AirSculpt uses its website as a channel of distribution for material Company information. Financial and other material information regarding AirSculpt is routinely posted on the Company's website and is readily accessible. About AirSculpt AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the federal U.S. securities laws. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” the negative of these terms and other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements, which are subject to risks, uncertainties, and assumptions about us, may include projections of our future financial performance (including in particular our projected 2026 revenue and adjusted EBITDA), our anticipated growth strategies, and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. You are cautioned that there are important risks and uncertainties, many of which are beyond our control, that could cause our actual results, level of activity, performance, or achievements to differ materially from the projected results, level of activity, performance or achievements that are expressed or implied by such forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements, including those factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K. Our future results could be affected by a variety of other factors, including, but not limited to, inability to sell equity or other securities in the future at a time when we might otherwise wish to effect sales; inability to raise capital on commercially reasonable terms, if at all; the risk that any future financings may dilute our stockholders or restrict our business; failure to stabilize same-store performance; not being able to optimize our marketing investment, go-to-market strategy and sales process; not having the ability to expand our financing options for consumers; being unsuccessful in further product innovations; failure to operate centers in a cost-effective manner; increased operating expenses due to rising inflation; increased competition in the weight loss and obesity solutions market, including as a result of the recent regulatory approval, increased market acceptance, availability and customer awareness of weight-loss drugs; shortages or quality control issues with third-party manufacturers or suppliers; competition for surgeons; litigation or medical malpractice claims; inability to protect the confidentiality of our proprietary information; changes in the laws governing the corporate practice of medicine or fee-splitting; changes in regulatory and macroeconomic conditions, including inflation and the threat of recession, economic and other conditions of the states and jurisdictions where our facilities are located; and business disruption or other losses from natural disasters, war, pandemic, terrorist acts or political unrest. The risk factors discussed in “Item 1A. Risk Factors” in our Annual Report on Form 10-K and in other filings we make from time to time with the SEC could cause our results to differ materially from those expressed in the forward-looking statements made in this press release. There also may be other risks and uncertainties that are currently unknown to us or that we are unable to predict at this time. Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. Forward-looking statements represent our estimates and assumptions only as of the date they were made, which are inherently subject to change, and we are under no duty and we assume no obligation to update any of these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated after the date of this press release to conform our prior statements to actual results or revised expectations, except as required by law. Given these uncertainties, investors should not place undue reliance on these forward-looking statements. Use of Non-GAAP Financial Measures The Company reports financial results in accordance with generally accepted accounting principles in the United States (“GAAP”), however, the Company believes the evaluation of ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. Although the Company provides guidance for Adjusted EBITDA, it is not able to provide guidance for net income, the most directly comparable GAAP measure. Certain elements of the composition of net income, including equity-based compensation, are not predictable, making it impractical for us to provide guidance on net income or to reconcile our Adjusted EBITDA guidance to net income without unreasonable efforts. For the same reasons, the Company is unable to address the probable significance of the unavailable information regarding net income, which could be material to future results. These non-GAAP financial measures are not intended to replace financial performance measures determined in accordance with GAAP. Rather, they are presented as supplemental measures of the Company's performance that management believes may enhance the evaluation of the Company's ongoing operating results. These non-GAAP financial measures are not presented in accordance with GAAP, and the Company’s computation of these non-GAAP financial measures may vary from similar measures used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to revenue, net income, operating income, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP. We report our financial results in accordance with GAAP, however, management believes the evaluation of our ongoing operating results may be enhanced by a presentation of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Loss and Adjusted Net Loss per Share, which are non-GAAP financial measures. We define Adjusted EBITDA as net loss excluding depreciation and amortization, net interest expense, income tax benefit, restructuring and related severance costs, one-time SOX compliance and other related costs, unrealized (gain)/loss, and equity-based compensation. We define Adjusted Net Loss as net loss excluding restructuring and related severance costs, one-time SOX compliance and other related costs, equity-based compensation and the tax effect of these adjustments. We include Adjusted EBITDA and Adjusted Net Loss because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA and Adjusted Net Loss each to be an important measure because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. Adjusted EBITDA has limitations as an analytical tool including: (i) Adjusted EBITDA does not include results from equity-based compensation and (ii) Adjusted EBITDA does not reflect interest expense on our debt or the cash requirements necessary to service interest or principal payments. Adjusted Net Loss has limitations as an analytical tool because it does not include results from equity-based compensation. We define Adjusted EBITDA Margin as Adjusted EBITDA as a percentage of revenue. We define Adjusted Net Loss per Share as Adjusted Net Loss divided by weighted average basic and diluted shares. We included Adjusted EBITDA Margin and Adjusted Net Loss per Share because they are important measures on which our management assesses and believes investors should assess our operating performance. We consider Adjusted EBITDA Margin and Adjusted Net Loss per Share to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net loss, the most directly comparable GAAP financial measure: The following table reconciles Adjusted Net Loss and Adjusted Net Loss per Share to net loss, the most directly comparable GAAP financial measure: Investor Contact Allison Malkin ICR, Inc. [email protected]